Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy - sprookjes - yvandenbroek - TriplyDB

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

http://www.wikidata.org/entity/Q29615215

about

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension Aldosterone antagonists for preventing the progression of chronic kidney disease Probucol for type 2 diabetes mellitus Prostaglandin E1 for preventing the progression of diabetic kidney disease Aldosterone antagonists for preventing the progression of chronic kidney disease Probucol for type 2 diabetes mellitus First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension Aldosterone antagonists for preventing the progression of chronic kidney disease Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease Advanced glycation end-products induce calpain-mediated degradation of ezrin Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease Angiotensin receptor blockers and myocardial infarction Standards of medical care in diabetes--2012 Avosentan reduces albumin excretion in diabetics with macroalbuminuria Access to health care among status Aboriginal people with chronic kidney disease Supramaximal dose of candesartan in proteinuric renal disease Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy Guidelines for the management of chronic kidney disease Polymorphism of the ACE Gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patients Informative noncompliance in endpoint trials Losartan and diabetic nephropathy: commentaries on the RENAAL study Neurohumoral stimulation in type-2-diabetes as an emerging disease concept A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice Recent advances in managing and understanding diabetic nephropathy Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses Role of Bone Marrow-Derived Fibroblasts in Renal Fibrosis The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy

P2860

Q22241786-B62887CC-B050-4CEE-B1D2-DE3D23FF2608 Q24186647-B1AAD855-D51D-4759-8DA6-A65FE6F06FC9 Q24194979-004DC825-03E1-44FE-964E-3FA349FB1083 Q24195163-5B88C411-6580-40C2-9774-8FADB5F9F947 Q24235251-6805AEAE-ECB7-46EE-83DB-6C54A6288B0D Q24239909-7D2100FD-0A93-4EAC-B7C3-123189F5C90D Q24240606-F9FF4D3A-4F3D-49F3-B642-95D87F87ACBE Q24240851-84DA3D06-7A4E-4A3D-9F5B-19963F589FB9 Q24243615-A614B066-BE18-42A9-A32E-A2F748F4A61D Q24244197-CE230A41-C18B-4CB3-9A8F-67141057887E Q24293645-F0BED107-190E-41E3-9095-DE9B08395D77 Q24320230-24A3CCB5-2116-4555-AAB6-E6BC2060C1B3 Q24559659-1E64803A-5C60-454B-A7D4-CCF3BC8DBFF7 Q24632533-36B444BB-0491-42E8-A309-C78EB67D88DA Q24642372-5BF0F827-6491-4685-BB42-6F1875D5C324 Q24648683-F355DB82-D030-4A71-94C1-78C454BD8D07 Q24649685-AF7B5EC0-8F0F-498A-8360-DC4284F5D1D4 Q24657470-44972AFC-AC5B-43BC-89DD-0C9B042C028E Q24657844-F0403C22-C5B9-4B21-B5E7-BED3A20D7203 Q24658206-1484C142-40D2-4D31-A6DA-22920F9EB255 Q24791524-DCC886D1-9D4C-49BB-9235-983A6EDF3FE9 Q24796010-D9E90D84-B3B5-4459-9A29-4A5BF52F7165 Q24798310-6FF4BBEF-C40B-46E6-A713-A82B8BCB4E00 Q24806038-66A702F0-680E-4E83-B0D8-835BEF611CE1 Q24811026-DB539E58-21A5-4A42-AD29-6FE3E1AE55CA Q24814563-6BB09F9F-3D31-4CF3-BA7A-9445CA182C3A Q25257883-889265FB-0CE5-4FCC-AB42-9B46B850FAF3 Q26739475-A9F05AAF-A967-4CB3-9661-2C4779F480E5 Q26740125-F26496C5-31FA-45C3-B567-C53E09961DCF Q26741451-D5192DEF-756A-46A3-A05D-BBCDC2C768C6 Q26741860-F71DCFF1-76C6-4258-A374-3FD64B4DCB2C Q26745900-FC893472-BEBC-4BF9-A281-31A3988BDE09 Q26747131-20C1EDAB-ACE4-4453-821E-15FBCF4A6A94 Q26766025-73B14E30-BECF-4125-A65C-C96B9E17B240 Q26766599-C908E0EE-CBC7-432F-900F-D2ED094C8027 Q26767011-7319EAFF-B0BD-45ED-BAF2-99E89254DB54 Q26767278-211A80B3-32ED-4977-8654-948540B282A4 Q26768585-80AE872C-44DC-4454-B10D-C52A7553AFF9 Q26768696-24B86C9F-82DF-45CB-8822-63E809DA5442 Q26771919-83254E7C-7AEB-4733-B285-D580008784CC

P2860

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

http://www.wikidata.org/entity/Q29615215

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Effects of losartan on renal a ...... ype 2 diabetes and nephropathy

@ast

Effects of losartan on renal a ...... ype 2 diabetes and nephropathy

@en

type

label

Effects of losartan on renal a ...... ype 2 diabetes and nephropathy

@ast

Effects of losartan on renal a ...... ype 2 diabetes and nephropathy

@en

prefLabel

Effects of losartan on renal a ...... ype 2 diabetes and nephropathy

@ast

Effects of losartan on renal a ...... ype 2 diabetes and nephropathy

@en

P1433

Q29615215-77A4349F-98C7-4001-B7B0-A6CCCE3C6B11

P1476

Q29615215-57176985-85F1-4A02-BF64-79EFB8271CF4

P2093

Q29615215-24F234F3-79C1-4230-A3F5-2721A634AD05

Q29615215-4B670A57-B1D2-4C14-998B-4DFA2EED6373

Q29615215-720DA612-D325-4C64-8038-DB1C2595F3E2

Q29615215-7862AB14-C6EA-4A5F-A35E-0FA89AEA16CA

Q29615215-991D396B-CB01-4140-83CC-D59FFCC1ECA4

Q29615215-A57D50E2-6FE0-44BD-8418-37EC4CE4765D

Q29615215-BBCDAC3B-3CD8-4602-8159-E6B1461DAEEE

Q29615215-D5AD96DE-5EB5-4732-AB87-A88CC487CD00

Q29615215-E3C78B9D-9C75-4162-BD5C-24F4FF5E9441

P304

Q29615215-540AFE52-A98A-48EA-AB8B-A37F082BFC95

P31

Q29615215-DD9D48B2-4843-4F4C-93DB-8568F357F894

P3181

Q29615215-F61C2C89-99A3-4579-8C0B-89DA873EFC5B

P356

Q29615215-25438E34-CF1A-422A-A77C-D2B4AFF21258

P407

Q29615215-69AAF889-DB3C-4F2D-B2C8-6FFA86835E6E

P433

Q29615215-2105B272-BC40-43AE-9FA2-ABDE2846AD51

P478

Q29615215-FA631F5C-854B-46E5-9D7F-3C9CF15F3997

P50

Q29615215-405E0414-5D8C-44A2-B0D7-7C73C227E5C3

P577

Q29615215-EFE9A5B2-2F4D-41A0-B1FB-470D5DAC19E2

P698

Q29615215-0CA72747-A77E-4373-93DA-7508A5A39222

P921

Q29615215-8180EB8E-55CD-4613-B9D8-C18BE2B4ECCF

Q29615215-FB3F0D08-5710-40BE-AD99-B24DD4C3C0D5

P3181

P356

P1433

The New England Journal of Medicine

P1476

Effects of losartan on renal a ...... ype 2 diabetes and nephropathy

@en

P2093

Brenner BM

http://www.w3.org/2001/XMLSchema#string

Cooper ME

http://www.w3.org/2001/XMLSchema#string

Keane WF

http://www.w3.org/2001/XMLSchema#string

Mitch WE

http://www.w3.org/2001/XMLSchema#string

Parving HH

http://www.w3.org/2001/XMLSchema#string

Shahinfar S

http://www.w3.org/2001/XMLSchema#string

Snapinn SM

http://www.w3.org/2001/XMLSchema#string

Zhang Z

http://www.w3.org/2001/XMLSchema#string

de Zeeuw D

http://www.w3.org/2001/XMLSchema#string

P304

861-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

476578

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA011161

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

345

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Remuzzi

P577

2001-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11565518

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

type-2 diabetes